LABELS · 7f47b815-d08b-46fe-aee9-d2cef6e86ec0

Nplate

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-23
Captured: 2026-09-09T23:37:51.659493+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 1.2 Patients with Hematopoietic Syndrome of Acute Radiation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.3) ] . Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP [see Warnings and Precautions ( 5.1 )] . Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts [see Warnings and Precautions ( 5.2 )] .

Full extracted label fields

application numbers

BLA125268

boxed warning exact

brand names

Nplate

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c45f9a58-37c1-4f76-8e36-97d38c577037

generic names

ROMIPLOSTIM

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

indications and usage exact

1 INDICATIONS AND USAGE Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 1.2 Patients with Hematopoietic Syndrome of Acute Radiation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.3) ] . Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP [see Warnings and Precautions ( 5.1 )] . Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts [see Warnings and Precautions ( 5.2 )] .

indications and usage tables exact

is original packager

true

manufacturer names

Amgen, Inc

matched search terms

myelodysplastic

package ndcs

55513-222-01
55513-222-21
55513-223-01
55513-223-21
55513-221-01
55513-221-21

product ndcs

55513-221
55513-222
55513-223

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions, Thrombotic/Thromboembolic Complications ( 5.2 ) 02/2025 Warnings and Precautions, Loss of Response to Nplate ( 5.3 ) 02/2025

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

1728092
1728095
1728097
1728099
2201538
2201540

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00400.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA125268

brand names

Nplate

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 460
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicate
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 0

current approval status

not_reconciled

duplicate text group

dup-2e03c5b4fd7f4fb8bcdd

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-0cb5f9cc06b392d85e9e

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

end: 77
end exclusive: true
exact text: is a thrombopoietin receptor agonist indicated
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 31

qualifier mentions

context exact
agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insuffic
kind
age
polarity
not_inferred
span
end
134
end exclusive
true
exact text
Adult patients
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
120

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 260
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

BLA125268

brand names

Nplate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 468
end exclusive: true
exact text: gonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to inc
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 61

current approval status

not_reconciled

duplicate text group

dup-ce8099854519d3033a34

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-0cefef0528901c24bfda

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 268
end exclusive: true
exact text: ( 1.1 )
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 261

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · positive indication candidate

application numbers

BLA125268

brand names

Nplate

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 633
end exclusive: true
exact text: ndicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 69

current approval status

not_reconciled

duplicate text group

dup-a8dc00e75203e7c07bcb

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-eee588efce4bac79623a

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

end: 77
end exclusive: true
exact text: is a thrombopoietin receptor agonist indicated
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 31

qualifier mentions

context exact
Pediatric patients 1 year of age and older with ITP for at least 6 months who
kind
age
polarity
not_inferred
span
end
287
end exclusive
true
exact text
Pediatric patients
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
269

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 433
end exclusive: true
exact text: Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 269

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · positive indication candidate

application numbers

BLA125268

brand names

Nplate

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 862
end exclusive: true
exact text: globulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 234

current approval status

not_reconciled

duplicate text group

dup-374e8cbad2a10d8118a8

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-fd2771f53b05fddd09ac

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

end: 461
end exclusive: true
exact text: is indicated
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 449

qualifier mentions

context exact
( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely
kind
age
polarity
not_inferred
span
end
492
end exclusive
true
exact text
adults
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
486
context exact
) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressi
kind
age
polarity
not_inferred
span
end
518
end exclusive
true
exact text
pediatric patients
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
500

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 662
end exclusive: true
exact text: ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]).
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 434

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · limitation of use

application numbers

BLA125268

brand names

Nplate

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1039
end exclusive: true
exact text: o increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 463

current approval status

not_reconciled

duplicate text group

dup-922c33328175a897e23e

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-10f4c16f394591c75d80

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 839
end exclusive: true
exact text: ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 663

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · unclassified context

application numbers

BLA125268

brand names

Nplate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1176
end exclusive: true
exact text: on Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patient
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 640

current approval status

not_reconciled

duplicate text group

dup-c50f68926d5e354417fd

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-89f2ec0eef9c9d8b0c29

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 976
end exclusive: true
exact text: Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 840

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · risk or warning

application numbers

BLA125268

brand names

Nplate

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1246
end exclusive: true
exact text: yndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient resp
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 777

current approval status

not_reconciled

duplicate text group

dup-038d6afe5bac1516286c

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-732406f30290bcaebbd9

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1046
end exclusive: true
exact text: Nplate should not be used in an attempt to normalize platelet counts.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 977

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · unclassified context

application numbers

BLA125268

brand names

Nplate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1252
end exclusive: true
exact text: should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response t
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 847

current approval status

not_reconciled

duplicate text group

dup-d73f3af5a613c746e430

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-ece1d6e37cf2dcda1bed

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1052
end exclusive: true
exact text: ( 1 )
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1047

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · positive indication candidate

application numbers

BLA125268

brand names

Nplate

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1503
end exclusive: true
exact text: be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 1.2 Patients with Hematopoietic Sy
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 853

current approval status

not_reconciled

duplicate text group

dup-90727d060f1133d45fad

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-5210dd93f03420ec5948

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

end: 1120
end exclusive: true
exact text: is indicated
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1108

qualifier mentions

context exact
late is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insuffic
kind
age
polarity
not_inferred
span
end
1177
end exclusive
true
exact text
Adult patients
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
1163

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1303
end exclusive: true
exact text: 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1053

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · positive indication candidate

application numbers

BLA125268

brand names

Nplate

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1668
end exclusive: true
exact text: ate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 1.2 Patients with Hematopoietic Syndrome of Acute Radiation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosup
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1104

current approval status

not_reconciled

duplicate text group

dup-a8dc00e75203e7c07bcb

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-fe62bd25cddd1e20722c

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

end: 1120
end exclusive: true
exact text: is indicated
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1108

qualifier mentions

context exact
Pediatric patients 1 year of age and older with ITP for at least 6 months who
kind
age
polarity
not_inferred
span
end
1322
end exclusive
true
exact text
Pediatric patients
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
1304

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1468
end exclusive: true
exact text: Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1304

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · positive indication candidate

application numbers

BLA125268

brand names

Nplate

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1928
end exclusive: true
exact text: , immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 1.2 Patients with Hematopoietic Syndrome of Acute Radiation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.3) ] . Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP [see Warnings and Precautions (
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1269

current approval status

not_reconciled

duplicate text group

dup-901b0b7afcda819372d6

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-259b2a7e3c3dd8dac400

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

end: 1557
end exclusive: true
exact text: is indicated
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1545

qualifier mentions

context exact
iation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely
kind
age
polarity
not_inferred
span
end
1588
end exclusive
true
exact text
adults
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
1582
context exact
e Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressi
kind
age
polarity
not_inferred
span
end
1614
end exclusive
true
exact text
pediatric patients
label id
7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start
1596

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1728
end exclusive: true
exact text: 1.2 Patients with Hematopoietic Syndrome of Acute Radiation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.3) ] .
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1469

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · limitation of use

application numbers

BLA125268

brand names

Nplate

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2137
end exclusive: true
exact text: Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.3) ] . Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP [see Warnings and Precautions ( 5.1 )] . Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1529

current approval status

not_reconciled

duplicate text group

dup-7b3ea13625a85eb37bbb

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-f5caa33578308c7cd485

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1937
end exclusive: true
exact text: Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP [see Warnings and Precautions ( 5.1 )] .
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1729

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 13 · unclassified context

application numbers

BLA125268

brand names

Nplate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2184
end exclusive: true
exact text: ns of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP [see Warnings and Precautions ( 5.1 )] . Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts [see Warnings and Precautions ( 5.2 )] .
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1738

current approval status

not_reconciled

duplicate text group

dup-c50f68926d5e354417fd

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-6703e8370615be80d101

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2074
end exclusive: true
exact text: Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding.
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1938

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · risk or warning

application numbers

BLA125268

brand names

Nplate

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2184
end exclusive: true
exact text: openia other than ITP [see Warnings and Precautions ( 5.1 )] . Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts [see Warnings and Precautions ( 5.2 )] .
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 1875

current approval status

not_reconciled

duplicate text group

dup-15a0937d9c58e06ed1f1

extraction review status

automated_candidate_pending_source_review

generic names

ROMIPLOSTIM

ind-span-ec5a718408b8d28e9ffb

label id

7f47b815-d08b-46fe-aee9-d2cef6e86ec0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2184
end exclusive: true
exact text: Nplate should not be used in an attempt to normalize platelet counts [see Warnings and Precautions ( 5.2 )] .
label id: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d146cb5a631dbb4cf35db269b1da9fc2f41a54e7087e736659e0d0673a58c9a0
start: 2075

source url

https://api.fda.gov/drug/label.json?search=id%3A%227f47b815-d08b-46fe-aee9-d2cef6e86ec0%22

spl effective date

2026-06-23

spl set id

c45f9a58-37c1-4f76-8e36-97d38c577037

spl version

162

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice